Asia Pacific Telecom launches “IoT by Gt Smart Life” multi-network platform for the Smart Island of Taiwan, powered by Actility ThingPark
Asia Pacific Telecom announced the launch of Taiwan's first IoT dual-network multi-platform, “IoT by Gt Smart Life,” after more than two years of research and development. Since the launch of Gt 4g, Asia-Pacific Telecom (APT) has been evolving into a non-traditional telecommunications company, with a commitment to develop a Smart Life and an IoT platform to build Taiwan into a Smart Island.
Local and international heavyweights have worked together to deliver this collaboration. Within the IoT by Gt Smart Life platform, Foxconn Technology Group provides the hardware, FH-Net deploys the LoRa network, and APT is responsible for the vital domain of application development and service delivery. Key partners include domestic and overseas manufacturers, such as Actility, IBM, Semtech, Cisco, Advantech and Shin Kong Security, spanning the midstream and downstream industries of wafers, platforms and terminals. Those who become a "Certified IoT by Gt Smart Life Partner" are entitled to free use of the LoRa network, implementing a shared economy.
LoRaWAN has advantages in range, time, coverage, and price. Hundreds of millions of networked devices to be built by 2020.
APT has broken with telecommunications tradition in building Taiwan's first IoT dual network, using the Low Power Wide Area Network (LPWAN) communications protocol in combination with the APT 4G LTE network, to support a wide variety of applications across a range of industries. APT has already rolled out 500 LoRaWAN hotspots, supporting Taiwan's first IoT network for Greater Taipei and Taoyuan. Responding to service requirements for solutions covering the entire island, Taiwan will be able to develop fully into a “Smart Island” by the end of 2016. By 2020, IoT Ecosystem partners in Taiwan are expected to have delivered hundreds of millions of networked devices, which will allow Taiwan to become the exemplary IoT nation, and expand into overseas markets.
LoRaWAN is the open standard solution, and is the most widely used low-power consumption long-range WAN protocol.
LoRaWAN is a global IoT success story. Almost 400 institutions or companies, with over 20 telecom providers, are member of the LoRa ™ Alliance, which was established thanks to the optimism of companies regarding business opportunities in the Smart City and the Smart Factory. Founded by Actility, Cisco, IBM, Semtech, Microchip and other technology leaders in 2015, the LoRa™ Alliance is an open, non-profit organization committed to the implementation of LoRaWAN as a long-range, low-cost and low-power consumption wide-area networking technology for IoT. The LoRa Alliance brings together many world-class companies to share knowledge and experience and together promote LoRaWAN network protocols and accelerate the global success of LoRaWAN.
Taiwan's first IoT dual-network multi-platform -- developers accelerate application innovation
The IoT by Gt dual-network platform supports both networks of LoRa hotspots and the existing 4G LTE, integrating partners such Cisco, Jasper, Actility, and IBM Bluemix into this dual-network. It provides developers with the most complete IoT solution and accelerates application innovation. Actility’s ThingPark IoT solution is at the heart of this platform. Actility is a technology innovator and industry leader in LPWA. ThingPark™ is the next generation standards-compliant IoT platform. Olivier Hersent, founder and CTO of Actility, comments: “Actility is proud to be working with FH-Net and APT to deliver this large-scale, fully operational LPWA roll-out, which immediately catapults Taipei to the forefront of the world’s leading IoT cities. We see this as a great opportunity to be at the heart of one of the most exciting IoT markets, which is preparing for explosive growth, and we look forward to continuing to work with APT to deploy new services and capabilities within the platform.”
IoT dual-network will enable a Smart Ecosystem: "Smart City" and "Tracking Service" are already online
The IoT by Gt platform solution has already launched the first demonstration applications, “Smart City” and “Tracking Service”.
Smart City Application: Using LoRa terminal devices, Energy Management Systems and Yung Loong Engineering will launch Smart Water/Electricity/Gas Meters with instant meter reading, history and anomaly warnings. In addition, the Security Institute of Science and Technology has launched a "Smart Water Level Gauge". The smart water level gauge integrates data transmission from water level gauge, solar charging and a cloud data platform, dramatically reducing the construction of monitoring stations and maintenance and operation costs.
"Tracking Service": This uses LoRa IoT to track vehicles, goods and pets to send instant location and provide “geo-fenced” alerts. Examples include the "LoRa Multipurpose Tracker", designed and developed by Foxconn Technology Group, weighing only 21 grams and combining GPS and Wifi. It is available for indoor and outdoor positioning; it also combines a customized Location Based System for real-time tracking. Added to this are multiple functions such as Path History, Electronic Fence, and Tracking Management, combining LoRa and tracking services.
In addition to the demonstrated "Smart City Applications" and "Tracking Service", IoT by Gt can be extended to Internet of Vehicles, Smart Factories, Smart Agriculture, Smart Home and other domains. IoT by Gt will support developers implementing innovative applications and create industry development opportunities for the new IoT generation in Taiwan.
For more information: www.thingpark.com.
Actility Press contact
Anne van Gemert
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 06:00 | Pressemelding
ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number
GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 05:01 | Pressemelding
GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30 | Pressemelding
Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30 | Pressemelding
Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom